Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.

被引：0
|
作者：
Hultcrantz, Malin
Kleinman, David
Ghataorhe, Pavandeep
McKeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne C.
Byrne, Julie
Eliason, Laurie
Scott, Emma Catherine
Opalinska, Joanna
机构：
[1] Mem Sloan Kettering Canc Ctr, Myeloma Serv, Dept Med, New York, NY USA
[2] Univ Rochester, Rochester, NY USA
[3] GlaxoSmithKline, London, England
[4] GlaxoSmithKline, Boston, MA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] GlaxoSmithKline, Upper Providence, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8073
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Recovery of ocular events with longer-term follow-up in the DREAMM-2 study of single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Jakubowiak, Andrzej
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 53 - 54
  • [22] The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
    Becnel, Melody R.
    Lee, Hans C.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [23] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
    Cohen, Adam D.
    Trudel, Suzanne
    Lonial, Sagar
    Libby, Edward N.
    Lee, Hans Chulhee
    Besemer, Britta
    Facon, Thierry
    Nooka, Ajay K.
    Callander, Natalie Scott
    Chari, Ajai
    Gupta, Ira
    Paul, Sofia
    Opalinska, Joanna
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
    Nooka, Ajay K.
    Stockerl-Goldstein, Keith
    Quach, Hang
    Forbes, Adam
    Mateos, Maria-Victoria
    Khot, Amit
    Tan, Alan
    Abonour, Rafat
    Chopra, Bikramjit
    Rogers, Rachel
    Ferron-Brady, Geraldine
    Davidge, Jacqueline
    Frey, Steve
    Yeakey, Anne
    Talekar, Mala
    Luptakova, Katarina
    Gupta, Ira
    Popat, Rakesh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
    Dimopoulos, Meletios Athanasios
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Perera, Sue
    Boyle, Julia
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Weisel, Katja
    LANCET HAEMATOLOGY, 2023, 10 (10): : E801 - E812
  • [26] Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
    Suvannasankha, Attaya
    Bahlis, Nizar J.
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Rocafiguera, Albert Oriol
    Voorhees, Peter M.
    Alonso, Aranzazu Alonso
    Callander, Natalie Scott
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne C.
    Zhou, Xiangdong
    Gupta, Ira V.
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2
    Kortuem, M.
    Trudel, S.
    Cohen, A. D.
    Richardson, P. G.
    Lonial, S.
    Opalinska, J. B.
    Gupta, I
    Byrne, J.
    Zhi, E.
    Baron, J.
    Morgan, L.
    Voorhees, P. M.
    Popat, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 97 - 98
  • [28] A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
    Dileo, Rachel
    Mewawalla, Prerna
    Babu, Kalaivani
    Yin, Yue
    Strouse, Christopher
    Chen, Ethan
    Shaikh, Hira
    Davis, James A.
    Green, Kimberly M.
    Alkharabsheh, Omar
    Rashid, Aliya
    Pokhrel, Bidushi
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [29] Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a
    Popat, Rakesh
    Augustson, Bradley
    Gironella, Mercedes
    Lee, Cindy
    Cannell, Paul
    Patel, Nashita
    Kasinathan, Ravi
    Rogers, Rachel
    Curry, Amy
    Carreno, Fernando
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Quach, Hang
    BLOOD, 2023, 142
  • [30] Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
    Lonial, Sagar
    Lee, Hans C.
    Badros, Ashraf
    Trudel, Suzanne
    Nooka, Ajay K.
    Chari, Ajai
    Abdallah, Al-Ola
    Callander, Natalie
    Sborov, Douglas
    Suvannasankha, Attaya
    Weisel, Katja
    Voorhees, Peter M.
    Womersley, Lynsey
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    CANCER, 2021, 127 (22) : 4198 - 4212
12345